New Leadership in Division of Urology:
Richie Steps Down, Kibel Appointed Chief

Read about other Transitions at BWH.

Dr. Jerome Richie and Dr. Adam Kibel

After 24 years as chief of the Division of Urology and chairman of the Harvard Program in Urology, Jerome Richie, MD, announced his decision to step away from the position to spend more time focusing on his patients, students and research. This fall, Adam Kibel, MD, joined BWH as the fifth chief of Urology.

Richie said that he is proud of all the division has accomplished in the last quarter century.

"In conjunction with more than 25 full-time faculty at five hospitals, we have built one of the premier urologic training programs in the country," said Richie, who also served for 10 years as chief of Urologic Oncology before he became chief of Urology. "I have had the privilege of educating and guiding more than 100 residents during my tenure, many of whom have gone on to distinguish themselves as professors and chiefs at other institutions."

Under Richie's leadership, the Urology Division became a team of internationally recognized leaders who have developed new therapies for prostate cancer, testicular cancer, benign prostate disease and bladder dysfunction. "I am equally proud of our close collaboration with medical and radiation oncologists through DF/BWCC to establish one of the earliest multidisciplinary clinics in urologic oncology and ensure that our patients receive the very best care available in the world," Richie said.

Richie looks forward to pursuing his clinical, research and teaching work at BWH with vigor, continuing to focus his surgical and clinical interests on treatment and eradication of urologic malignancies.

He is succeeded as chief by Kibel, who trained under Richie's direction at the Harvard Program of Urology from 1993 to 1997.

Kibel joined BWH this fall from the Washington University School of Medicine in St. Louis-one of the top urology programs in the nation. A busy clinician and funded researcher, Kibel specializes in the surgical treatment of all forms of urologic cancers, Kibel said he is "humbled by the opportunity to follow in Dr. Richie's footsteps and lead the Urology program at the Brigham and Dana-Farber."

Kibel previously served as professor of Urologic Surgery and Genetics, the director of Urology Oncology, and co-director of Robotic Surgery in the Division of Urology.  In addition, he was the director of the Urologic Oncology Fellowship Program, ombudsman for the Department of Surgery and director of the Prostate Cancer Program for the Alvin J. Siteman Cancer Center.  His leadership will be invaluable to the Dana Farber/Brigham and Women's Cancer Center's Urologic Cancer Disease program.

Kibel earned his MD at Cornell University Medical College in 1991. He completed his two preliminary residency years in General Surgery at BWH in 1993.  He also completed a uro-oncology fellowship at the Brady Urological Institute at Johns Hopkins Medical Institutions, where he trained under Dr. Patrick Walsh, former institute chairman who also trained at the Brigham.

Kibel's research focuses on the molecular basis of genitourinary malignancies, and he has received grants from the American Cancer Institute and the National Cancer Institute, as well as through the American Recovery and Reinvestment Act.